What does this research mean for the field?

The Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT) occurs in approximately 7.6% of lithium poisoning cases and can be accurately predicted using a clinical model based on routine variables, whereas serum lithium levels alone are not predictive. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

To determine the incidence, clinical risk factors, and prognostic indicators of the Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT) following acute or chronic lithium poisoning.

September 8, 2026Clinical ToxicologyOpen Access

Predicting SILENT after lithium poisoning: a multicenter cohort study and pragmatic risk stratification model

View Full Paper

Ask AI

Bookmark

Authors

ÁPÁlvaro Pineda-TorcuatoHospital Universitario Puerta de Hierro Majadahonda ACAntonio F Caballero-BermejoUniversidad Nebrija ASAugust SupervíaUniversidad Mayor de San Andrés

Discussion

Member takes

Implication

Multicenter cohort study reveals irreversible neurotoxicity in 7.6% of lithium poisoning cases, indicating routine clinical markers predict long-term risk better than blood lithium levels.

Key Points

To determine the incidence, clinical risk factors, and prognostic indicators of the Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT) following acute or chronic lithium poisoning.
Retrospective, international, multicenter cohort study analyzing 644 adult episodes evaluated for lithium poisoning across 23 tertiary hospitals in Spain, Ireland, and Switzerland (2015–2022).
Defined the primary outcome, SILENT, as persistent neurological sequelae attributed to lithium toxicity documented at 60 days post-exposure.
Developed a parsimonious multivariable logistic regression model using routinely available clinical variables, assessed through ROC analysis and internal split-sample validation (n=456).
SILENT was identified in 49 of 644 episodes (7.6%), occurring more frequently in older patients with acute-on-chronic poisoning, early neurological features (ataxia and myoclonus), higher Poisoning Severity Scores, and elevated peak urea.
Serum lithium concentrations at presentation showed no significant association with the development of SILENT.
The clinical prediction model demonstrated good discrimination (AUC 0.813; 95% CI 0.743–0.882) and acceptable internal validation (AUC 0.730; 95% CI 0.572–0.888), with a sensitive cutoff (P ≥ 0.0475) achieving a 98.2% negative predictive value.

Cite This Study

Pineda-Torcuato et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd7ab58e84d0ff5b46814 https://doi.org/10.1080/15563650.2026.2693677

View Full Paper

Ask AI

Bookmark

September 8, 2026Clinical ToxicologyOpen Access

Predicting SILENT after lithium poisoning: a multicenter cohort study and pragmatic risk stratification model

View Full Paper

Ask AI

Bookmark

Authors

ÁPÁlvaro Pineda-TorcuatoHospital Universitario Puerta de Hierro Majadahonda ACAntonio F Caballero-BermejoUniversidad Nebrija ASAugust SupervíaUniversidad Mayor de San Andrés

Discussion

Member takes

Implication

Multicenter cohort study reveals irreversible neurotoxicity in 7.6% of lithium poisoning cases, indicating routine clinical markers predict long-term risk better than blood lithium levels.

Key Points

To determine the incidence, clinical risk factors, and prognostic indicators of the Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT) following acute or chronic lithium poisoning.
Retrospective, international, multicenter cohort study analyzing 644 adult episodes evaluated for lithium poisoning across 23 tertiary hospitals in Spain, Ireland, and Switzerland (2015–2022).
Defined the primary outcome, SILENT, as persistent neurological sequelae attributed to lithium toxicity documented at 60 days post-exposure.
Developed a parsimonious multivariable logistic regression model using routinely available clinical variables, assessed through ROC analysis and internal split-sample validation (n=456).
SILENT was identified in 49 of 644 episodes (7.6%), occurring more frequently in older patients with acute-on-chronic poisoning, early neurological features (ataxia and myoclonus), higher Poisoning Severity Scores, and elevated peak urea.
Serum lithium concentrations at presentation showed no significant association with the development of SILENT.
The clinical prediction model demonstrated good discrimination (AUC 0.813; 95% CI 0.743–0.882) and acceptable internal validation (AUC 0.730; 95% CI 0.572–0.888), with a sensitive cutoff (P ≥ 0.0475) achieving a 98.2% negative predictive value.

Cite This Study

Pineda-Torcuato et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd7ab58e84d0ff5b46814 https://doi.org/10.1080/15563650.2026.2693677

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark